MaxCyte, Inc. (AIM:MXCT)
152.00
-8.00 (-5.00%)
Inactive · Last trade price
on Jun 25, 2025
MaxCyte Revenue
MaxCyte had revenue of $10.39M USD in the quarter ending March 31, 2025, a decrease of -8.39%. This brings the company's revenue in the last twelve months to $37.68M, down -14.48% year-over-year. In the year 2024, MaxCyte had annual revenue of $38.63M, down -6.44%.
Revenue (ttm)
$37.68M
Revenue Growth
-14.48%
P/S Ratio
5.55
Revenue / Employee
$330.48K
Employees
114
Market Cap
161.75M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 38.63M | -2.66M | -6.44% |
Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMaxCyte News
- 2 days ago - MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 10 days ago - PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
- 4 weeks ago - MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies - GlobeNewsWire
- 2 months ago - MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - GlobeNewsWire
- 2 months ago - A Look at MaxCyte's Upcoming Earnings Report - Benzinga
- 3 months ago - MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire
- 4 months ago - MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha